Vanguard Group’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$163M Sell
13,828,355
-75,380
-0.5% -$813K ﹤0.01% 1652
2025
Q3
$107M Sell
13,903,735
-227,026
-2% -$1.59M ﹤0.01% 1828
2025
Q2
$103M Sell
14,130,761
-126,355
-0.9% -$1.02M ﹤0.01% 1819
2025
Q1
$135M Buy
14,257,116
+17,229
+0.1% +$215K ﹤0.01% 1653
2024
Q4
$235M Buy
14,239,887
+195,793
+1% +$3.04M ﹤0.01% 1472
2024
Q3
$207M Sell
14,044,094
-77,396
-0.5% -$1.21M ﹤0.01% 1527
2024
Q2
$196M Sell
14,121,490
-89,529
-0.6% -$1.27M ﹤0.01% 1510
2024
Q1
$223M Buy
14,211,019
+41,354
+0.3% +$638K ﹤0.01% 1450
2023
Q4
$229M Sell
14,169,665
-146,536
-1% -$2.4M 0.01% 1425
2023
Q3
$176M Sell
14,316,201
-324,613
-2% -$4.83M ﹤0.01% 1495
2023
Q2
$235M Buy
14,640,814
+770,257
+6% +$12.7M 0.01% 1385
2023
Q1
$241M Buy
13,870,557
+195,812
+1% +$2.79M 0.01% 1353
2022
Q4
$126M Buy
13,674,745
+500,037
+4% +$4.66M ﹤0.01% 1673
2022
Q3
$113M Sell
13,174,708
-141,693
-1% -$1.41M ﹤0.01% 1714
2022
Q2
$109M Buy
13,316,401
+345,898
+3% +$3.3M ﹤0.01% 1766
2022
Q1
$158M Buy
12,970,503
+113,534
+0.9% +$2.39M ﹤0.01% 1693
2021
Q4
$439M Buy
12,856,969
+186,607
+1% +$7.31M 0.01% 1085
2021
Q3
$611M Buy
12,670,362
+472,802
+4% +$21.9M 0.02% 857
2021
Q2
$551M Buy
12,197,560
+168,921
+1% +$7.48M 0.01% 936
2021
Q1
$580M Buy
12,028,639
+861,061
+8% +$44.8M 0.02% 868
2020
Q4
$601M Buy
11,167,578
+284,828
+3% +$12.9M 0.02% 787
2020
Q3
$401M Sell
10,882,750
-357,852
-3% -$13.3M 0.01% 866
2020
Q2
$348M Buy
11,240,602
+462,957
+4% +$12.8M 0.01% 937
2020
Q1
$298M Buy
10,777,645
+264,642
+3% +$7.93M 0.01% 897
2019
Q4
$308M Buy
10,513,003
+81,178
+0.8% +$1.93M 0.01% 1112
2019
Q3
$199M Buy
10,431,825
+2,258,111
+28% +$53M 0.01% 1334
2019
Q2
$179M Buy
8,173,714
+2,401,227
+42% +$52.7M 0.01% 1427
2019
Q1
$118M Buy
5,772,487
+1,678,162
+41% +$29.2M ﹤0.01% 1660
2018
Q4
$51.6M Buy
4,094,325
+254,684
+7% +$3.8M ﹤0.01% 2008
2018
Q3
$58.9M Buy
3,839,641
+743,245
+24% +$10.3M ﹤0.01% 2067
2018
Q2
$40.6M Buy
3,096,396
+36,581
+1% +$403K ﹤0.01% 2236
2018
Q1
$25M Buy
3,059,815
+104,112
+4% +$843K ﹤0.01% 2407
2017
Q4
$26.2M Buy
2,955,703
+68,629
+2% +$633K ﹤0.01% 2376
2017
Q3
$32.1M Buy
2,887,074
+162,471
+6% +$1.58M ﹤0.01% 2274
2017
Q2
$24.4M Buy
2,724,603
+44,820
+2% +$356K ﹤0.01% 2371
2017
Q1
$21.1M Buy
2,679,783
+176,691
+7% +$1.44M ﹤0.01% 2418
2016
Q4
$21.5M Buy
2,503,092
+238,446
+11% +$2.04M ﹤0.01% 2393
2016
Q3
$18.6M Buy
2,264,646
+134,133
+6% +$1.13M ﹤0.01% 2392
2016
Q2
$17.1M Buy
2,130,513
+441,119
+26% +$3.54M ﹤0.01% 2396
2016
Q1
$11.4M Buy
1,689,394
+93,298
+6% +$614K ﹤0.01% 2544
2015
Q4
$12.6M Buy
1,596,096
+23,602
+2% +$173K ﹤0.01% 2515
2015
Q3
$9.01M Buy
1,572,494
+138,715
+10% +$859K ﹤0.01% 2662
2015
Q2
$7.76M Buy
1,433,779
+122,998
+9% +$634K ﹤0.01% 2806
2015
Q1
$6.12M Buy
1,310,781
+115,997
+10% +$504K ﹤0.01% 2895
2014
Q4
$4.98M Buy
1,194,784
+26,569
+2% +$122K ﹤0.01% 2904
2014
Q3
$6.09M Buy
1,168,215
+385,466
+49% +$1.98M ﹤0.01% 2729
2014
Q2
$2.6M Sell
782,749
-50,129
-6% -$167K ﹤0.01% 3145
2014
Q1
$2.89M Buy
832,878
+150,085
+22% +$562K ﹤0.01% 3063
2013
Q4
$2.47M Buy
682,793
+4,492
+0.7% +$15.6K ﹤0.01% 3107
2013
Q3
$2.04M Buy
678,301
+288,652
+74% +$813K ﹤0.01% 3125
2013
Q2
$1.55M Buy
+389,649
New +$1.49M ﹤0.01% 3156

Other funds holding NEO

Vanguard Group's NEO Position: Q4 2025 in Review

Vanguard Group reduced its NeoGenomics (NEO) stake by 0.54% in Q4 2025, selling an estimated $813K and leaving 13,828,355 shares worth $163M. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

Vanguard Group first reported a position in NEO in Q2 2013 and has held it in 51 quarters since. The position peaked at $611M in Q3 2021. 256 funds tracked by Wall St. Rank hold NEO as of Q4 2025.

  • Vanguard Group held 13,828,355 shares of NeoGenomics worth $163M as of Q4 2025.
  • Vanguard Group sold 75,380 NeoGenomics shares in Q4 2025, an estimated $813K.
  • NeoGenomics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1652 holding.
  • Vanguard Group first reported a position in NeoGenomics in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's NeoGenomics position peaked at $611M in Q3 2021.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.